San Diego-based drug developer Meritage Pharma raised $2 million in a round of equity-based financing planned to total $5.5 million, an SEC filing indicates. Meritage is out to develop a treatment for a little-known ailment called eosinophilic esophagitis, in which an allergic reaction causes a patient’s esophagus to swell, sometimes to the point where food becomes lodged in it. Previous investors in Meritage, which launched a trial of its treatment in January 2009, include Domain Associates, Latterell Venture Partners, and The Vertical Group.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
